INmune Bio, Inc. (NASDAQ:INMB) Receives $18.40 Consensus PT from Analysts

INmune Bio, Inc. (NASDAQ:INMB) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $18.40.

A number of brokerages have recently weighed in on INMB. Wall Street Zen lowered INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday, August 2nd. Maxim Group lowered their target price on INmune Bio from $30.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, July 2nd. BTIG Research reiterated a “neutral” rating on shares of INmune Bio in a research note on Tuesday, July 1st. Raymond James Financial lowered INmune Bio from a “moderate buy” rating to a “hold” rating in a research note on Monday, June 30th. Finally, Scotiabank reissued a “sector underperform” rating on shares of INmune Bio in a research report on Tuesday, July 1st.

INmune Bio Stock Up 1.0%

INMB stock opened at $1.99 on Friday. The business has a 50 day moving average price of $2.34 and a two-hundred day moving average price of $5.49. The company has a market cap of $52.89 million, a price-to-earnings ratio of -0.80 and a beta of 1.03. INmune Bio has a twelve month low of $1.71 and a twelve month high of $11.64.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.03. On average, equities research analysts anticipate that INmune Bio will post -2.24 EPS for the current fiscal year.

Institutional Investors Weigh In On INmune Bio

Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its position in INmune Bio by 14.4% during the first quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after buying an additional 2,409 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in INmune Bio during the first quarter worth approximately $180,000. Two Sigma Investments LP grew its position in INmune Bio by 444.8% during the fourth quarter. Two Sigma Investments LP now owns 66,384 shares of the company’s stock worth $310,000 after buying an additional 54,200 shares in the last quarter. Bank of America Corp DE grew its position in INmune Bio by 15.2% during the fourth quarter. Bank of America Corp DE now owns 30,449 shares of the company’s stock worth $142,000 after buying an additional 4,015 shares in the last quarter. Finally, Two Sigma Advisers LP acquired a new stake in INmune Bio during the fourth quarter worth approximately $59,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.